Jo Shorthouse
Interim Editor of In Vivo
Jo Shorthouse has contributed to various Citeline publications, starting with Scrip in 2008. She has previously edited Scrip Good Clinical Practice, Scrip Clinical Research and the Scrip 100, been a managing editor on Pharma Intelligence commercial team, and most recently turned her hand to freelance health care journalism and editorial consultancy. Jo has a wide-ranging knowledge of many aspects of the pharmaceutical industry which allows her to bring insights to the Citeline and In Vivo teams.
Latest From Jo Shorthouse
Flight Of The Navigator: Bluebird bio's Andrew Obenshain
For 12 years, bluebird bio has been developing gene therapies for rare genetic disease and now, with two approvals under its belt, the company is continuing to explore uncharted territory as it brings forward innovative new treatments. Holding the map is CEO Andrew Obenshain.
Lessons From Novo Nordisk’s Mads Øvlisen, The Father Of CSR
When Mads Øvlisen was persuaded by his father-in-law to join the family business, Novo Industri, in 1974 for a short stint in the legal department, little did he know it would the beginning of a lifetime of service to the company that he helped to shape into the diabetes powerhouse it is today.
Lessons From Novo Nordisk’s Mads Øvlisen, The Father Of CSR
When Mads Øvlisen was persuaded by his father-in-law to join the family business, Novo Industri, in 1974 for a short stint in the legal department, little did he know it would the beginning of a lifetime of service to the company that he helped to shape into the diabetes powerhouse it is today.
The Journey Has Just Begun For LAG-3 Therapeutics
Clinical stage innovator Immutep talks to In Vivo about the potential for LAG-3 antibodies in cancer and autoimmune diseases.
Reviving A Longsuffering Neuro Company: The Marinus Story
Marinus Pharmaceuticals’ CEO spoke candidly to In Vivo about breathing new life into ultra-rare epilepsy disorder drug ganaxolone.
The New Generation Of Investor: Creating Value From Diamonds In The Rough
Debbie Dumont, co-founder of Bioqube Ventures, and one of In Vivo’s Rising Leaders, talks about the company’s investment model, Europe’s translational challenges, and aligning passion and purpose to find ultimate fulfilment.